Alveo’s Portable, Rapid Molecular Diagnostic Platform Proves Unshakable in Rigorous Ruggedness Tests

Neither a one-meter drop nor constant motion and vibration prevent the device from completing tests with near 100% accuracy, proving its utility at Point of Need™ in virtually any environment

Alveo Technologies, Inc. (Alveo), a leader in molecular sensing and diagnostics with its proprietary technology platform, today announced the results of rigorous testing that demonstrate the ruggedness of its portable molecular testing platform. Whether it fell from a significant height, endured temperature and humidity extremes, or was subjected to jarring vibrations that mimic vehicle transportation of virtually any type — the device continued to complete tests and produce accurate results.

Alveo’s rapid molecular diagnostic platform has been designed to provide accurate, rapid test results at the point of need. The company tested its platform to demonstrate that it can perform reliably in harsh, real-world conditions, where markets, applications and use cases previously did not exist due to this unmet market need and requirement.

  • Specifically, the Alveo platform underwent the following tests:
    Environmental resilience: The device was placed in controlled chambers at 5 degrees Celsius and 40 degrees Celsius at up to 95% humidity for 24 hours.
    Movement and vibration: At a third-party facility, the platform was subjected to constant motion and vibration for nearly four hours (233 minutes and 34 seconds), simulating what the device would experience in the back of a moving delivery truck.
  • Drop testing: The device was dropped from up to 1 meter in height onto a hardwood board.
  • Cleaning: The analyzer was wiped down 100s of times with five different common disinfectants, including commercial bleach, isopropyl alcohol and hydrogen peroxide.

The results demonstrate that the Alveo platform can accurately perform tests in the field, under the most extreme of conditions. In the environmental resilience, drop, and cleaning tests, the device completed tests with 100% accuracy, and in the movement and vibration test, it also performed at 100% accuracy when the LED was facing up. When the LED was facing down during the vibration and movement test, it completed tests with 94% accuracy. The company is actively working on its next generation platform, enabling 360-degree capability with 100% accuracy.

“These tests thoroughly demonstrate our platform’s ability to provide consistent performance at the point of need, whether testing takes place in fields, on farms and in animal pens, remote locations, disaster zones, and beyond,” said Shaun Holt, CEO at Alveo. “Our rugged design and innovative molecular detection technology make it possible for healthcare providers, veterinarians, growers, and public health officials to obtain rapid, accurate results at the point of need, enabling them to take immediate action to treat and contain diseases, bacteria, fungi, and other contaminants. Alveo is leading the way by delivering a system that works in harsh environments where fast, easy testing without compromise is needed most. This study verifies that we can produce PCR-like results for a whole new set of applications, use cases, and a much broader user base than traditional molecular diagnostic methods.”

For more information on how the Alveo platform performed during ruggedness testing, read the full report: Built for Point of Need™ Detection: Ruggedness Testing of the Alveo Analyzer https://alveotechnologies.com/rugged.

Sourcet

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”